spacer
home > ebr > spring 2017 > culture clash
PUBLICATIONS
European Biopharmaceutical Review

Culture Clash

Serum has long been an integral media component of cell culture, providing a rich source of diverse nutrients vital for successful in vitro culture. Fetal bovine serum (FBS) is the preferred serum source for cell culture for several reasons. First, FBS is highly accessible and accommodating to most cell types and is therefore the most widely used supplement for mammalian cell culture Ė including human primary cells. Second, it consists of a broad spectrum of components like proteins, growth factors, enzymes and other chemical constituents that make it ideal for promoting cell health and growth. Third, it provides a broad spectrum of utility such as attachment and spreading, detoxifying and transport factors attributed to a serumís complex structure (1,2).

Lot-to-Lot Variability

Although FBS can be utilised across a wide array of cell types from various sources (including multiple different species), one major disadvantage is its lot-to-lot variability, which is also observed in other serum compositions such as human serum albumin (HSA). This variability stems from the numerous natural and chemical components that contribute to its complex structure, which is attributed to the varying conditions and parameters observed during processing and collection. For example, inconsistency in batch sizes; the number and age of animals used; the potential presence of varying amounts of endotoxins; and other pathogen-associated contaminants can all influence each lotís quantitative and qualitative consistency and performance. This necessitates the regular screening of multiple FBS lots prior to purchase in order to maintain a consistent experimental and/or manufacturing output. Additionally, even when the ideal lot has been identified, the culture effects can still vary from one cell type to the next. This impacts the ability to utilise a single lot for multiple applications and poses a challenge for translational and human clinical studies.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Since joining Irvine Scientific in 2012, Jessie HT Ni has been leading the R&D team in developing improved CD, ACF culture media for major primary cells and cell lines. She received her PhD in Molecular Biology and post-doctoral training in Immunology from University of Minnesota, US, and also has a Masterís degree in Management of Technology from Carlson School of Management, University of Minnesota.
spacer
Jessie HT Ni
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The 3rd CEE Pharmaceutical Manufacturing Excellent Awards Were Handed Out

More than 400 decision makers and professionals attended PHARM Connect this year from over 25 countries with the same purpose: sharing their experiences, building new partnerships, finding the best solutions for their company and preparing for the challenges of the new regulations.
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Inkís eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

Clinical Trial Supply West Coast conference 2017

24-25 May 2017, Burlingame, California

Clinical Trial Supply West Coast returns in 2017 this time in Burlingame. Attracting the leading biotech and pharma companies from Northern California and beyond, the event will focus on how drug companies can adapt their supply chains to fit into the highly regulated world. For the first time key topics will be explored through Debates, Workshops and extended Roundtable discussions. With standout presenters from Sanofi, Genentech, Dynavax and Gilead, this is an event not to miss out on Ė reserve your place today!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement